Clinical trials: Gastric (Stomach) Cancer
Gastric Cancer, Type 2 Diabetes
Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes
Gastric bypass improves glycemic levels in type 2 diabetes. However, the efficacy may be varied by different gastric-small intestine reconstruction used in the procedure.
- Trial name
- NCT01528059
- Testing
- Stomach-small intestine reconstruction
- Where
- China
- Volunteers
- 110 people
- Sponsor
- feng Zheng
Metastatic Gastric Cancer
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
To evaluate safety and response rate of durvalumab/tremelimumab in combination with paclitaxel in patients with metastatic gastric cancers who fail a first-line chemotherapy
- Trial name
- NCT03751761
- Testing
- durvalumab, tremelimumab, paclitaxel
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Asan Medical Center
Adenocarcinoma of the Stomach, GastroEsophageal Cancer
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX, with modified FOLFOX plus Nivolumab and Ipilimumab or FLOT plus Nivolumab.
- Trial name
- NCT03647969
- Testing
- Nivolumab, Ipilimumab, mFOLFOX
- Where
- 27 sites in Germany
- Volunteers
- 262 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Gastric Cancer
Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer
This is a Phase II Trial of Perioperative Chemotherapy with Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6)in Patients with Locally Advanced Operable Gastric Cancer.
- Trial name
- NCT02142322
- Testing
- MODIFIED FOLFOX6
- Where
- 2 sites in South Korea
- Volunteers
- 52 people
- Sponsor
- Seoul National University Hospital
Advanced Gastric Cancer, Neoadjuvant Therapy
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate…
- Conditions
- Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis
- Trial name
- NCT06376773
- Testing
- combination chemotherapy with Apatinib or Camrelizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Fujian Medical University
Stomach Neoplasms
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
- Trial name
- NCT00553696
- Testing
- Cisplatin, S-1, Sunitinib
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Pfizer
Gastric Cancer
The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
A study from our group (Osterkamp et al. in preparation) used ICG to evaluate intraoperative changes in gastric perfusion when reducing the circulating blood volume by blood withdrawal in pigs.
- Trial name
- NCT05354856
- Testing
- Indocyanine green
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Gastric Cancer
Observational Study of Perioperative Chemotherapy in Gastric Cancer
This study will assess the efficacy and toxicity of perioperative chemotherapy with Epirubicin + Cisplatin + Capecitabine (ECX) in routine clinical practice in a network of public hospitals in Santiago, Chile.
- Trial name
- PRECISO (NCT01633203)
- Testing
- epirubicin + cisplatin + capecitabine polychemotherapy
- Where
- Chile
- Volunteers
- 61 people
- Sponsor
- Grupo Oncologico Cooperativo Chileno de Investigation
Gastric Intestinal Metaplasia
The Predictive Scores for Gastric Cancer in Gastric Intestinal Metaplasia (GIM) Patient: a Recommendation for Thai Population
The predictive scores for gastric cancer in gastric intestinal metaplasia(GIM) patient: a recommendation for Thai population. Objective: To evaluate major risk factors for gastric cancer in gastric intestinal metaplasia(GIM)…
- Trial name
- NCT01490541
- Where
- Thailand
- Volunteers
- 280 people
- Sponsor
- King Chulalongkorn Memorial Hospital
HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
Trastuzumab deruxtecan's (T-DXd's) efficacy and safety has been confirmed in traditional clinical trials, there is a lack of real-world evidence, especially among Chinese patients.
- Trial name
- RECOVER (NCT06846996)
- Testing
- Trastuzumab deruxtecan (T-DXd)
- Where
- 40 sites in China
- Volunteers
- 260 people
- Sponsor
- Daiichi Sankyo
Endoscopic Submucosal Dissection
Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study
The purpose of this study is to evaluate the feasibility, ease and safety of flexible endoscopic robotic system to treat early gastric cancer in humans.
- Trial name
- ESD (NCT01394861)
- Testing
- ESD using Master Slave Robotic System
- Where
- India
- Volunteers
- 3 people
- Sponsor
- Asian Institute of Gastroenterology, India
Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer
Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-PD-1 immunotherapy. The trial is designed using a pick-the-winner strategy.
- Trial name
- TORCH-G (NCT06728657)
- Testing
- HFRT targeted to the primary lesion and positive lymph nodes, PULSAR targeted to the primary lesion and positive lymph nodes, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Esophageal Cancer, Gastric Cancer
Sorafenib. ICORG 06-41, V4
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01158287
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in Ireland
- Volunteers
- 54 people
- Sponsor
- Cancer Trials Ireland
Stomach Cancer
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant…
- Trial name
- NCT04135781
- Testing
- nab paclitaxel, Tegafur, Oxaliplatin
- Where
- China
- Volunteers
- 616 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Outlet Obstruction
Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy
Gastric outlet obstruction (GOO) occurs commonly in malignancies involving the periampullary region (cancers originating in the head of the pancreas, duodenum, bile duct, or ampulla) or the distal stomach.
- Trial name
- EAT-GO (NCT05561907)
- Testing
- Surgical gastrojejunostomy (SGJ), Endoscopic gastrojejunostomy (EGJ)
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwell Health
Esophageal Cancer, Gastric Cancer
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab in combination with trastuzumab and chemotherapy, has on the patients' esophagogastric cancer.
- Trial name
- NCT02954536
- Testing
- pembrolizumab, trastuzumab, capecitabine
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Gastric Cancer
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types
- Trial name
- NCT05610332
- Testing
- Camrelizumab, Albumin Taxol, FLOT scheme
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Fujian Medical University
Gastric Cancer
The Safety of Totally Laparoscopic Versus Laparoscopy-Assisted Total Gastrectomy.
To compare the short-term surgical safety and postoperative quality of life of totally laparoscopic versus laparoscopy-assisted total gastrectomy and to evaluate the superiority of totally laparoscopic total gastrectomy.
- Trial name
- NCT04351321
- Testing
- Totally Laparoscopic Total Gastrectomy, Laparoscopy-Assisted Total Gastrectomy
- Volunteers
- 560 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cancer
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
This is a Phase Ib, open-label, dose-escalation study to determine the Maximal tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) for the combination of afuresertib and paclitaxel in subjects with recurrent…
- Trial name
- NCT02240212
- Testing
- Afuresertib, Paclitaxel
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Solid Neoplasms, Colorectal Neoplasms
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.
- Conditions
- Solid Neoplasms, Colorectal Neoplasms, Gastrointestinal Tumors
- Trial name
- NCT03833700
- Testing
- E7386
- Where
- 8 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.